marked.bio

Company

Amgen

7 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

sotorasib 4pembrolizumab 4panitumumab 3bevacizumab 1daraxonrasib 1trametinib 1vociprotafib 1afatinib 1atezolizumab 1palbociclib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

7 of 17 trials shown

  1. Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Amgen Started 2024Primary completion 2028-09 NCT06252649

    FOLFIRIsotorasib FDA EUpanitumumab FDAbevacizumab

    Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.

    KRAS G12CMetastatic Colorectal Cancer

  2. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    Recruiting Phase 3 Amgen Started 2023Primary completion 2027-06 NCT05920356

    sotorasib FDA EUpembrolizumab

    G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing…

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC)

  3. AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

    Recruiting Phase 1 Amgen Started 2026Primary completion 2030-01 NCT07403721

    AMG 436

    Histologically confirmed MSI-H or dMMR metastatic or locally advanced solid tumor by local testing or central testing.

    MSI-H / dMMRMetastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

  4. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 Amgen Started 2025Primary completion 2028-04 NCT07094113

    AMG 410pembrolizumabpanitumumab FDA

    Pathologically documented, locally-advanced or metastatic malignancy with any missense mutation in the KRAS gene or evidence of KRAS amplification using an analytically validated KRASWT amplificati…

    KRAS G12CKRAS G12DKRAS Altered Advanced or Metastatic Solid Tumors

  5. Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

    Active, not recruiting Phase 1 Amgen Started 2024Primary completion 2026-10 NCT06333951

    Anvumetostatcarboplatinpaclitaxelpembrolizumabpemetrexedsotorasib FDA EU

    Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.

    KRAS G12CThoracic Tumors, Non-small Cell Lung Cancer

  6. A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

    Active, not recruiting Phase 1 Amgen Started 2024Primary completion 2026-10 NCT06360354

    Anvumetostatgemcitabinenab-paclitaxelFOLFIRINOXdaraxonrasib

    Rat Sarcoma Viral Oncogene Homolog (RAS) mutation

    KRAS G12CKRAS G12DAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

  7. Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Active, not recruiting Phase 1 Amgen Started 2019Primary completion 2026-12 NCT04185883

    sotorasib FDA EUtrametinibvociprotafibafatinibpembrolizumabpanitumumab FDAcarboplatinpemetrexeddocetaxelpaclitaxelatezolizumabpalbociclib

    Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…

    KRAS G12CAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation